Article
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.
Cancer - 1 Feb 2026
DiLeo Mckenzie, Oglesby Samantha, Leung Cheuk Hong, Pauken Kristen E, Farooq Sahira, Haydu Lauren E, Kubicki Shelby L, Martinez Rebeca, Welborn Macartney, Zahiruddin Sana, Zou Jun, Cao Kai, Patel Anisha B
Abstract excerpt
BACKGROUND: While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune-related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI monotherapy and combination therapy. As certain HLA types are indicative of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.